Project: Pre-clinical and clinical validation of a next-generation gabapentinoid for Neuropathic Pain
| Acronym | Drug for Neuropathic Pain (Reference Number: 113249) |
| Duration | 06/01/2020 - 07/01/2022 |
| Project Topic | Validation of analgesic candidate NVA1309 to deliver: 1) GLP/Toxicology to estimate dose range for Phase I, guided by animal toxicity and 2) Completion of Ph I studies in healthy volunteers to generate pharmacokinetic/safety profiling and dose range for Ph IIa (Clinical Proof of Concept,C-PoC). This project exceeded threshold TWICE (ranked 70th and 78th in 2018 calls), but not funded due to Swiss budgetary restrictions. This is a re-submission addressing comments raised by reviewers. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 11 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Novassay SA | Coordinator | Switzerland |
| 2 | 3A(UK) Limited | Partner | United Kingdom |
| 3 | Richmond Pharmacology Limited | Partner | United Kingdom |